Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-12-24
1999-09-28
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514337, 514432, 514456, 546256, 5462801, 5462827, 549 49, 549 51, 549396, 549408, C07D31158, C07D33506, C07D40506, A61K 3135
Patent
active
059589540
ABSTRACT:
2,2-Dialkyl-4-aryl-substituted benzopyran and benzothiopyran derivatives of the formula ##STR1## where the symbols have the meaning described in the specification, have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists.
REFERENCES:
patent: 4096341 (1978-06-01), Frazer
patent: 4326055 (1982-04-01), Loeliger
patent: 4391731 (1983-07-01), Boller et al.
patent: 4485252 (1984-11-01), Fuchs et al.
patent: 4539154 (1985-09-01), Krebs
patent: 4695649 (1987-09-01), Magami et al.
patent: 4723028 (1988-02-01), Shudo
patent: 4739098 (1988-04-01), Chandraratna
patent: 4740519 (1988-04-01), Shroot, et al.
patent: 4810804 (1989-03-01), Chandrafatna
patent: 4826969 (1989-05-01), Maignan et al.
patent: 4826984 (1989-05-01), Berlin et al.
patent: 4833240 (1989-05-01), Maignan et al.
patent: 4855320 (1989-08-01), Chatterjee et al.
patent: 4895868 (1990-01-01), Chandraratna
patent: 4923884 (1990-05-01), Chandraratna
patent: 4927947 (1990-05-01), Chandraratna
patent: 4980369 (1990-12-01), Chandraratna
patent: 4992468 (1991-02-01), Chandraratna
patent: 5006550 (1991-04-01), Chandraratna
patent: 5013744 (1991-05-01), Chandraratna
patent: 5015658 (1991-05-01), Chandraratna
patent: 5023341 (1991-06-01), Chandraratna
patent: 5037825 (1991-08-01), Klaus et al.
patent: 5045551 (1991-09-01), Chandraratna
patent: 5053523 (1991-10-01), Chandraratna
patent: 5068252 (1991-11-01), Chandraratna
patent: 5089509 (1992-02-01), Chandraratna
patent: 5130335 (1992-07-01), Chandraratna
patent: 5134159 (1992-07-01), Chandraratna
patent: 5162546 (1992-11-01), Chandraratna
patent: 5175185 (1992-12-01), Chandraratna
patent: 5183827 (1993-02-01), Chandraratna
patent: 5202471 (1993-04-01), Chandraratna
patent: 5231113 (1993-07-01), Chandraratna
patent: 5234926 (1993-08-01), Chandraratna
patent: 5248777 (1993-09-01), Chandraratna
patent: 5264456 (1993-11-01), Chandraratna
patent: 5264578 (1993-11-01), Chandraratna
patent: 5272156 (1993-12-01), Chandraratna
patent: 5278318 (1994-01-01), Chandraratna
patent: 5310662 (1994-05-01), Evans et al.
patent: 5324744 (1994-06-01), Chandraratna
patent: 5324840 (1994-06-01), Chandraratna
patent: 5326898 (1994-07-01), Chandraratna
patent: 5344959 (1994-09-01), Chandraratna
patent: 5346895 (1994-09-01), Chandraratna
patent: 5346915 (1994-09-01), Chandraratna
patent: 5348972 (1994-09-01), Chandraratna
patent: 5348975 (1994-09-01), Chandraratna
patent: 5349105 (1994-09-01), Chandraratna
patent: 5354752 (1994-10-01), Chandraratna
patent: 5354776 (1994-10-01), Chandratatna
patent: 5380877 (1995-01-01), Chandraratna
patent: 5391753 (1995-02-01), Chandraratna
patent: 5399561 (1995-03-01), Chandraratna
patent: 5399586 (1995-03-01), Davies et al.
patent: 5407937 (1995-04-01), Chandraratna
patent: 5414007 (1995-05-01), Chandraratna
patent: 5420145 (1995-05-01), Shudo
patent: 5426118 (1995-06-01), Chandraratna
patent: 5434173 (1995-07-01), Chandraratna
patent: 5451605 (1995-09-01), Chandraratna et al.
patent: 5455265 (1995-10-01), Chandraratna
patent: 5466861 (1995-11-01), Dawson et al.
patent: 5468879 (1995-11-01), Chandraratna
patent: 5470999 (1995-11-01), Chandraratna
patent: 5475022 (1995-12-01), Chandraratna
patent: 5475113 (1995-12-01), Chandraratna
patent: 5489584 (1996-02-01), Vuligonda et al.
patent: 5498755 (1996-03-01), Chandraratna
patent: 5498795 (1996-03-01), Song et al.
patent: 5514825 (1996-05-01), Vuligonda et al.
patent: 5516904 (1996-05-01), Chandraratna
patent: 5523457 (1996-06-01), Starrett, Jr. et al.
patent: 5534516 (1996-07-01), Chandraratna
patent: 5534641 (1996-07-01), Song et al.
patent: 5543534 (1996-08-01), Vuligonda et al.
patent: 5556996 (1996-09-01), Beard et al.
patent: 5559248 (1996-09-01), Starrett, Jr. et al.
patent: 5563292 (1996-10-01), Shih et al.
patent: 5571696 (1996-11-01), Evans et al.
patent: 5578483 (1996-11-01), Evans et al.
patent: 5591858 (1997-01-01), Vuligonda et al.
patent: 5599819 (1997-02-01), Chandraratna
patent: 5599967 (1997-02-01), Vuligonda et al.
patent: 5602130 (1997-02-01), Chandraratna
patent: 5602135 (1997-02-01), Chandraratna
patent: 5605915 (1997-02-01), Vuligond et al.
patent: 5616597 (1997-04-01), Chandraratna
patent: 5616712 (1997-04-01), Teng et al.
patent: 5618836 (1997-04-01), Chandraratna et al.
patent: 5618839 (1997-04-01), Starrett, Jr. et al.
patent: 5618931 (1997-04-01), Beard et al.
patent: 5618943 (1997-04-01), Vuligonda et al.
patent: 5648385 (1997-07-01), Starrett, Jr. et al.
patent: 5648503 (1997-07-01), Vuligonda et al.
patent: 5648514 (1997-07-01), Johnson et al.
patent: 5654469 (1997-08-01), Vuligonda et al.
patent: 5663347 (1997-09-01), Chandraratna
patent: 5663357 (1997-09-01), Teng et al.
patent: 5663367 (1997-09-01), Vuligonda et al.
patent: 5672710 (1997-09-01), Beard et al.
patent: 5675024 (1997-10-01), Teng et al.
patent: 5675033 (1997-10-01), Vuligonda et al.
patent: 5677320 (1997-10-01), Chandraratna
patent: 5677323 (1997-10-01), Chandraratna
patent: 5677451 (1997-10-01), Chandraratna
patent: 5688957 (1997-11-01), Teng et al.
patent: 5696162 (1997-12-01), Chandraratna
patent: 5698700 (1997-12-01), Song et al.
patent: 5717094 (1998-02-01), Chandraratna
patent: 5723620 (1998-03-01), Vuligonda et al.
patent: 5723666 (1998-03-01), Vuligonda et al.
patent: 5728846 (1998-03-01), Vuligonda et al.
patent: 5739338 (1998-04-01), Beard et al.
A General Synthesis of Terminal and Internal Arylalkynes by the Palladium-Catalyzed Reaction of Alkynylzinc Reagents with Aryl Halides by Anthony O. King and Ei-ichi, J. Org. Chem., (1978) 43/2: p. 358.
Conversion of Methyl Ketones into Terminal Acetylenes and (E)-Tri-substituted Olefins of Terpenoid Origin by Ei-ichi, et al., J. Org. Chem., (1980) 45/12: p. 2526.
Sporn et al. in J. Amer. Acad. Derm., (1986) 15:756-764.
Teng et al., J. Med. Chem. 1997 40 2445-2451 Identification of High Potent Retinoic Acid Receptor .alpha.-Selective Antagonists.
"A Convenient Synthesis of Ethynylarenes and Diethynylarenes" by S. Takahashi et al. Synthesis (1980) pp. 627-630.
Shudo et al. Chem. Phar. Bull., (1985) 33:404-407.
Kagechika et al. in J. Med. Chem., (1988) 31:2182-2192.
Chemistry and Biology of Synthetic Retinoids by Marcia I. Dawson and William II. Okamura, published by CRC Press Inc., 1990, pp. 334-335, 354.
Synthesis of 2,2'-Diacyl-1,1'-Biaryls. Regiocontrolled Protection of . . . by Mervic, et al, J. Org. Chem., (1980) No. 45, pp. 4720-4725.
A Dopamine Receptor Model and Its Application in the Design of a New Class American Chemical Societe, (1981) 24/9:1026-1031.
6.2.3 Conformational Restriction, Williams, et al., Drug Discovery and Development, The Humana Press, (1987) pp. 54-55.
V. Retinoid Structure-Biological Activity Relationships, Chemistry and Biology of Synthetic Retinoids, (1990) pp. 324-356.
Davis et al. J. Organomettalic Chem (1990) 387:381-390.
"Effects of 13-Cis-Retinoic Acid, All Trans-Retinoic Acid and Acitretin on the Proliferation, Lipid Synthesis and Keratin Expression of Cultured Human Sebocytes in Vitro" C.C. Zouboulis, The Journal of Investigative Dermatology, (1991) 96/5:792-797.
"Organ Maintenance of Human Sebaceous Glands: in Vitro Effects of 13-Cis Retinoic Acid and Testosterone", John Ridden, et al., Journal of Cell Science (1990) 95:125-136.
"Characterization of Human Sebaceous Cells in Vitro", Thomas I. Doran, et al. The Journal of Investigative Dermatology, (1991) 96/3:.
"Synthesis and Evaluation of Stilbene and Dihydrostilbene Derivateives as Potential Anticancer Agents That Inhibit Tubulin Polymerization" by Cushman, Mark et al. J. Med. Chem., (1991) 34:2579-2588.
"Synthesis and Evaluation of New Pretoein Tyrosine Kinase Inhibitors. Part 1. Pyridi
Beard Richard L.
Chandraratna Roshantha A.
Duong Tien T.
Gillett Samuel J.
Johnson Alan T.
Allergan Sales Inc.
Baran Robert J.
Rao Deepak R.
Shah Mukund J.
Szekeres Gabor L.
LandOfFree
Synthesis and use of retinoid compounds having negative hormone does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthesis and use of retinoid compounds having negative hormone , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthesis and use of retinoid compounds having negative hormone will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-703780